New research reveals that people who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who end traditional diet and exercise regimens.
Published data in a major health publication demonstrates that while obese individuals frequently drop a large proportion of their body weight while using the jabs, the weight returns at an average rate of nearly a kilo each month after stopping.
"People buying such drugs need to be aware of the danger of rapid weight regain when the treatment ends," cautioned expert Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight in about a year and a half.
Analyzing Approaches
The analysis, which reviewed 37 of trials involving thousands of patients, contrasted the results of the injectable medications with conventional dieting.
Researchers emphasize that individuals who lose weight through diet and exercise typically see a less rapid weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Experts suggest the mechanism of the drugs explains the accelerated weight return.
These medications imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making excessive eating far more likely."
A Chronic Condition?
Medical guidelines recommend the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Professionals say that, due to the high risk of relapse, the therapy is often long-term.
This perspective is reinforced by drug manufacturers, who state that the results "emphasize the long-term nature of obesity," similar to managing conditions like high blood pressure.
Patient Experiences
People who have come off the medication report a powerful resurgence of appetite.
"I experienced a trigger that goes on and I was suddenly ravenous," described an individual.
This challenge is compounded if patients have not adopted permanent lifestyle or habit changes during therapy.
Growing Use
Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is greater among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Finally, experts stress that while the jabs are potent agents for weight loss, they are not a magic solution and maintained weight loss hinges on combined behavioural changes.
